Additional Research Studies

A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy

This is the Nexus Narcolepsy registry, a joint venture of Jazz Pharmaceuticals, Narcolepsy Network, and Wake Up Narcolepsy. See NOW RECRUITING people with narcolepsy internationally: CLICK HERE to register.

Stanford University’s Kleine-Levin Syndrome Study

NOW RECRUITING people who have ever had KLS: CLICK HERE.

The Nuvigil and Provigil Pregnancy Registry

NOW RECRUITING pregnant women with narcolepsy, sleep apnea, and shift work disorder in the USA: CLICK HERE.

Pitolisant Expanded Access for Patients with Narcolepsy

NOW RECRUITING people with narcolepsy in the USA: CLICK HERE. See also: Clinical

Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)

NOW RECRUITING in the U.S.: CLICK HERE. Axsome Therapeutics is enrolling people with narcolepsy with cataplexy (only) for a study of the efficacy of AXS-12 (reboxetine) for treatment of cataplexy and excessive daytime sleepiness. AXS-12 is an oral norepinephrine reuptake inhibitor (NRI).

Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy

NOW RECRUITING in the USA: CLICK HERE. Jazz Pharmaceuticals also has a study arm for OSA (obstructive sleep apnea), which is also RECRUITING – CLICK HERE. And a separate 4-week study of safety, efficacy, and pharmacokinetics of JZP-110 in Parkinson’s disease with excessive daytime sleepiness, which is also currently RECRUITING – CLICK HERE. There are also several separate studies of JZP-110, which are ongoing but no longer recruiting: 1) 12-week safety and efficacy in OSA – CLICK HERE; 2) 12-week safety and efficacy in narcolepsy – CLICK HERE; 3) long-term safety in narcolepsy and OSA – CLICK HERE; and 4) 6-week study of safety and efficacy in OSA – CLICK HERE. See Past Research Studies tab for current results.

A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

Jazz Pharmaceuticals’ trial completed: CLICK HERE. ADX-N05 is another name for JZP-110, as above.

XW Labs’ Phase 1 Study in Australia for Treatment of Narcolepsy with XW10172

See XW Labs Initiates First-in-Human Phase I Study for Novel Narcolepsy Treatment.

Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson’s Disease

NOW RECRUITING in S. Korea: CLICK HERE. Medicine available for off-label treatment in the USA.

A Study to Evaluate the Safety and Efficacy of TS-091 in Patients With Narcolepsy

NOW RECRUITING in Japan and S. Korea: CLICK HERE. The pharma company, Taisho, notes HERE that this drug is for central disorders of hypersomnolence.

Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Patients with Narcolepsy

NOW RECRUITING in Japan: CLICK HERE. TAK-925 is an orexin 2 receptor agonist.

Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients

Theranexus THN102 (modafinil/flecanide combo).  NOW RECRUITING in France: CLICK HERE. For more info: 1) First Clinical Study Completed on Effectiveness of Possible Narcolepsy Drug THN102. Flecainide is “an antiarrhythmic agent used in this instance at very low dosages and for its modulating effects on the glial connexins”; and 2) Hungary OKs Phase 2 Clinical Trial of Drug Candidate for Excessive Daytime Sleepiness in Parkinson’s.

Exploration of the Reward System by Functional MRI in Narco-cataplexy Patients With and Without REM Sleep Behavior Disorder


Investigation of Clinical Feature and Brain Function in Narcoleptic Patients

NOW RECRUITING at Tangdu Hospital in Xi’an, Shaanxi Province, China: CLICK HERE.

Get SomnusNooze, our monthly e-newsletter

Sign up to receive HF updates, news from the world of sleep research, first-person stories, and more.

You will receive an email from (please check your junk/spam folder if needed) to confirm your subscription to our newsletter through MailChimp. You are not subscribed until you confirm. Thank you for your interest in Hypersomnia Foundation!